Document Details

Document Information

0d07578b-f2f9-45d8-9edd-5281127378fb

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availabi

https://storage.googleapis.com/polarys-documents/uploads/2406f202-1666-403d-b9eb-4ac7bd94e9c9.txt

press_release

Executives Communication Type CEO Company CEO

None

2026-04-01

N/A

48

676

Actions
Query with AI Auto Tags
Document Content 
# Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

**Date:** 2026-04-01 07:30:00
**Company:** Vertex Pharmaceuticals Incorporated
**Ticker:** VRTX
**Source URL:** https://www.businesswire.com/news/home/20260401690804/en/Vertex-Announces-US-FDA-Approval-for-Label-Extensions-of-ALYFTREK%C2%AE-and-TRIKAFTA%C2%AE-Expanding-Availability-of-These-Medicines-to-95-of-All-People-With-CF-in-the-United-States/

---

Powered and protected by

![Akamai](https://www.akamai.com/site/ko/images/logo/akamai-logo1.svg)

[Privacy](https://www.akamai.com/privacy)